Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
GMAB enters Wednesday's Q3 results on a firmer footing than it held just weeks ago, with the stock up 10% over the past month to DKK 2,377 and the borrow market offering almost no signal of conviction from short sellers.
The lending picture is unambiguous in its message: bears have little practical presence here. Availability is extraordinarily loose, with roughly 57 shares available to borrow for every one currently lent out, well above the 52-week tightest level reached in early September when that ratio compressed to around 22. Cost to borrow remains negligible at 0.76%, barely moving week to week. Short interest itself is a marginal factor at best, with ORTEX utilization data showing just 1.7% of the lending pool in use. The options market carries no dramatic signal either, leaving the setup defined more by what is absent than what is present: there is no obvious short-side pressure or hedging intensity heading into the release.
The bull and bear debate around Genmab is ultimately a pipeline story. Bulls point to a P/E near 23x and an EV/EBITDA around 14x for a company that ranks in the 81st percentile on both 30-day and 90-day EPS momentum, a combination that implies the Street has been revising estimates upward with some consistency. The ORTEX short score of 32 is low, reflecting the thin bearish positioning, and the dividend score factor ranks in the 72nd percentile, an unusual positive for a biotech. The bear case rests on EPS surprise, which ranks in just the 12th percentile, meaning the company has tended to disappoint relative to consensus estimates at prior prints. The mean analyst price target sits at DKK 2,460, a modest 3.5% above the current price, suggesting the Street sees limited near-term upside even after the recent rally.
That tension between strong estimate momentum and a weak surprise track record is sharpened by recent earnings history. The August 2026 print produced a 5.7% single-day gain and a 7% five-day follow-through. The May 2026 report went the other way, with a 7.2% drop on the day and an additional 4.5% loss over the following week. Peers including GILD and SOBI have pulled back 4% and 2% respectively over the past week while Genmab has advanced, which either reflects genuine stock-specific optimism or sets a higher bar for the print to clear. Institutional ownership adds a layer of stability: Orbis holds 7.2% and BlackRock 7%, with AllianceBernstein and Paradigm Biocapital both adding meaningfully to positions in recent months.
Wednesday's print will test whether the company's estimate momentum reflects genuine operational progress or simply a lowered bar following May's disappointment.
See the live data behind this article on ORTEX.
Open GMAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
